Loading clinical trials...
Loading clinical trials...
Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of Subcutaneously and Orally Administered Prophylactic Vaccination With 2nd Generation (E1/E2B/E3-Deleted) Adenoviral COVID-19 in Normal Healthy Volunteers
Conditions
Interventions
hAd5-S-Fusion+N-ETSD (Suspension for injection)
hAd5-SFusion+ N-ETSD (Oral capsule)
Locations
2
United States
Chan Soon - Shiong Institute for Medicine
El Segundo, California, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
Start Date
February 24, 2021
Primary Completion Date
July 11, 2022
Completion Date
January 9, 2023
Last Updated
October 15, 2024
NCT07189936
NCT04525716
NCT03188796
NCT04527315
NCT05013632
NCT06355232
Lead Sponsor
ImmunityBio, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions